What We're Reading: Page 250
Industry reads hand-picked by our editors
Jul 16, 2018
-
The Wall Street Journal
This Form of Ambien Now Costs Over 800% More
-
Bloomberg
Beating the Next Superbug Needs a Big Pharma Payoff
-
The Boston Globe
Biotech revolution can serve the animal kingdom
Jul 13, 2018
-
Bloomberg
Many drugmakers ignore Trump — and raise prices anyway
-
The Wall Street Journal
South Korea regulator says Samsung BioLogics violated accounting rules
-
CNBC
Alphabet Verily, ResMed to spin out a start-up to address sleep apnea
-
Financial Times
The drug pricing playbook: how pharma companies keep costs high
Jul 12, 2018
-
Reuters
With U.S. trade under a cloud, China opens to Indian pharma
-
STAT
CRISPR makes cancer cells turncoats that attack tumor, mouse study finds
-
Xconomy
EU regulators approve Akcea's inotersen. FDA decisions are next.
-
NPR
Experimental drugs boost elderly immune systems, raising hopes for anti-aging effects
Jul 11, 2018
Jul 10, 2018
-
Southern Investigative Reporting Foundation
Acadia Pharmaceuticals: This is not a pharmaceuticals company
-
The Atlantic
Anti-vaxxers are targeting a vaccine for a virus deadlier than Ebola
-
NPR
Scientists find new tricks for old drugs
-
Science
Hidden conflicts?
Jul 09, 2018
-
Forbes
Vivek Ramaswamy's Enzyvant asks FDA to approve treatment for dying babies
-
Bloomberg
Bankers quit Goldman, Citigroup for biotech riches in Hong Kong
-
San Francisco Chronicle
Berkeley boy was ‘Patient X’ in first FDA-approved medicine derived from marijuana
-
FierceBiotech
Abingworth raises $315M to place transatlantic biotech bets
Previous
